NNZ-2591
Appearance
![]() | |
Clinical data | |
---|---|
Other names | Cyclo(L-glycyl-L-2-allylproline) |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C10H14N2O2 |
Molar mass | 194.234 g·mol−1 |
3D model (JSmol) | |
| |
|
NNZ-2591 is a synthetic analog of cyclic glycine-proline and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome,[1][2] and Prader-Willi syndrome.[3]
References
[edit]- ^ Markati, Theodora; Duis, Jessica; Servais, Laurent (3 July 2021). "Therapies in preclinical and clinical development for Angelman syndrome". Expert Opinion on Investigational Drugs. 30 (7): 709–720. doi:10.1080/13543784.2021.1939674.
- ^ Heussler, Helen S. (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome". Current Opinion in Psychiatry. 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. ISSN 0951-7367. S2CID 230663523.
- ^ "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614". clinicaltrials.gov. Retrieved 6 December 2023.